Visoluten

Visoluten is peptide complex A-7, extracted from the retinal tissue of young calves at 10 mg per capsule. It sits in the same lineage as Retinalamin, an injectable retinal peptide preparation used in Russian ophthalmology for retinal dystrophy and given by subconjunctival or intramuscular injection - and that lineage is where the credibility such as it is comes from. Visoluten itself is a swallowed capsule that must clear digestion, the systemic circulation and the blood-retinal barrier to do anything, and none of those steps has been demonstrated.

Targets: Retinal photoreceptors, Retinal pigment epithelium

• · 10 mg of peptide complex per capsule.

Work out your exact syringe units →

• uncommonMild digestive upset— Often excipient-related.
• rareAllergic reaction to bovine protein— Animal-tissue-derived product.

• Any sudden change in vision, new floaters or flashes - that needs an ophthalmologist the same day, not a supplement course.
• Known bovine protein allergy.
• Pregnancy and breastfeeding - no data.
• Do not use it to defer treatment for wet AMD or diabetic retinopathy, both of which have effective therapies and a narrow window.

• synergylutein-zeaxanthin — Frequently stacked for macular support; the AREDS2 nutrients have actual randomised trial data behind them and Visoluten does not.
• synergyghk-cu — Occasionally paired in ocular-surface protocols, though neither has ophthalmic outcome data in this format.

• · An Amsler grid used weekly at home is a free, genuinely useful way to catch macular change - use it regardless of whether you run this.
• · Keep your normal optometry or ophthalmology schedule; OCT imaging is the real measure.

Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.

• Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)
• Anisimov & Khavinson, peptide bioregulation of aging: results and prospects (Biogerontology) (review)

There is no mechanism on file. No indexed primary literature exists for Visoluten, and the credibility the product borrows comes entirely from Retinalamin, a separate injectable retinal peptide preparation used in Russian ophthalmology for retinal dystrophy and given by subconjunctival or intramuscular injection. That lineage argument is doing all the work, and it collapses on the route: a subconjunctival injection places material adjacent to the eye, bypassing every barrier that a swallowed capsule must cross. The blood-retinal barrier is the crux. It is formed by tight junctions in the retinal capillary endothelium and the retinal pigment epithelium, it excludes most large and charged molecules from the systemic circulation, and the entire modern practice of intravitreal anti-VEGF injection exists because of it. Asking a bovine retinal peptide fraction to reach photoreceptors after breakfast is asking for a great deal without any evidence that it happens. It is worth adding what does work, because the contrast is stark: the AREDS2 formulation - lutein, zeaxanthin, vitamin C, vitamin E, zinc and copper - has randomised trial data showing reduced progression to advanced age-related macular degeneration in people with intermediate disease. That is a swallowed supplement with a real trial and a real effect, and it costs a fraction of this.

Delay costs sight here, and unlike most of this class the window is measured in days. Wet age-related macular degeneration treated promptly with intravitreal anti-VEGF preserves vision; treated late it does not, and the damage is permanent. Retinal detachment presenting as new floaters, flashes or a curtain across the visual field is a same-day emergency. Diabetic macular oedema has effective treatment on a schedule. Anyone attributing early distortion to eye strain and running capsule courses for three months while waiting to see if it improves is in the worst possible position. The rule with this compound is simple: it never delays an eye appointment, and any new visual symptom overrides it entirely.

• No identified receptor or molecular target — None published

  Nothing has been characterised for this preparation.

• Retinal photoreceptors and retinal pigment epithelium (claimed)

  Manufacturer claim by analogy with the injectable Retinalamin. Neither systemic delivery nor blood-retinal barrier transit has been demonstrated for an orally dosed peptide complex.

Nothing acute and nothing perceptible. Weeks three to four: the window in which users describe reduced eye strain or improved visual comfort, which is also well within the range of normal variation in screen-related asthenopia and responds to a great many things including sleep and a break from screens. Months: no imaging or acuity endpoint has ever been published for this product at any timepoint. The measure that matters is the OCT scan at your optometrist or ophthalmologist, and it is measuring your retina, not the capsule.

Visoluten with lutein and zeaxanthin is the standard stack, and it is worth being precise about which half has evidence: the AREDS2 nutrient formulation has randomised trial data for slowing progression of intermediate age-related macular degeneration to the advanced form. Visoluten has none. If that stack helps anyone, it is the carotenoids and the zinc. The other genuinely evidence-based measures for eye health are unexciting: not smoking, which is the strongest modifiable risk factor for macular degeneration, controlling blood pressure and glucose, and attending screening.

Against the AREDS2 formulation: AREDS2 has randomised, multi-year, thousands-of-participants data for slowing progression of intermediate macular degeneration, and costs a few dollars a month. That comparison should settle the purchase decision on its own. Against intravitreal anti-VEGF for wet AMD or diabetic macular oedema: those are sight-saving treatments with unambiguous evidence, and no oral product substitutes for them. Against Retinalamin: an injectable with established Russian ophthalmological use - a different product by a different route whose evidence does not transfer. Against omega-3 for dry eye: even that mixed literature contains randomised trials.

$70–$200/month. A 20-capsule bottle covers ten to twenty days depending on dose. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.

• ?No indexed primary literature exists for Visoluten under this name.
• ?Oral bioavailability of the peptide complex has never been measured.
• ?Blood-retinal barrier transit has never been measured and is mechanistically the most demanding delivery claim in this class.
• ?No ophthalmic endpoint - acuity, OCT, contrast sensitivity, progression rate - has ever been published for this product.
• ?My attempt to retrieve the Retinalamin literature failed during this session, so I could not verify the strength of the injectable lineage the product borrows from. Treat the Retinalamin comparison as reported rather than confirmed.
• ?Composition is not published lot by lot.
• ?Cost figures are indicative estimates and were not verified against live vendor listings in this session.

• Peptide bioregulation of aging: results and prospects Anisimov VN, Khavinson VKh, Biogerontology, 2010 · PMID 19830585

  The programme overview. There is no Visoluten-specific citation to offer because no indexed primary literature on this product exists.

• Short Peptides Regulate Gene Expression Khavinson VK, Lin'kova NS, Tarnovskaya SI, Bulletin of Experimental Biology and Medicine, 2016 · PMID 27909961

  The general gene-regulation model that the retinal claims are extrapolated from.